Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market www.otcmarkets.com and www.asx.com.au.Additional disclosure required by listing rule 3.10.5A
|Shares currently on issue||156,196,558|
|Shares to be issued under LR7.1 placement capacity||23,141,984||14.82||%|
|Shares to be issued under LR7.1A placement capacity||15,594,656||9.98||%|
|Total Shares on issue after completion of the Placement||194,933,198||24.80||%|
The Company believes the benefits from funds raised in this placement at a discount to the 15-day VWAP of 11.9% outweigh the inability of shareholders to participate. The placement was not underwritten and direct costs of the raising are up to 7.5% of funds raised.
Further Information: Website: www.medibio.com.au Medibio Shareholder Enquiries: Jack Cosentino CEO and Managing Director Medibio Limited email@example.com T: +1 (952) 465 4787 Australian Media Enquiries: Peter Taylor NWR Communications firstname.lastname@example.org T: +61 (0) 412 036 231
Copyright © 2017 - Todos os direitos reservados para o Grupo Estado.As notícias e cotações deste site possuem delay de 15 minutos.